Remission & chronicity
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.
CTLA4
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| TREMELIMUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| IPILIMUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CYCLOSPORINE | ? unclear | Mechanistic | DGIdb | |
| ATEZOLIZUMAB | ? unclear | Mechanistic | DGIdb | |
| VISILIZUMAB | ? unclear | Mechanistic | DGIdb | |
| BLEOMYCIN | ? unclear | Mechanistic | DGIdb | |
| ANTIBIOTIC | ? unclear | Mechanistic | DGIdb | |
| METHIMAZOLE | ? unclear | Mechanistic | DGIdb | |
| RETRO-INVERSO PEPTIDE | ? unclear | Mechanistic | DGIdb | |
| MELPHALAN | ? unclear | Mechanistic | DGIdb | |
| RECOMBINANT FAS LIGAND | ? unclear | Mechanistic | DGIdb | |
| ZALIFRELIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| RIBAVIRIN | ? unclear | Mechanistic | DGIdb | |
| ANTI-THYMOCYTE GLOBULIN | ? unclear | Mechanistic | DGIdb | |
| QUAVONLIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 32 [PMID: 20471253] | ↓ inhibits | Mechanistic | DGIdb | |
| SIROLIMUS | ? unclear | Mechanistic | DGIdb | |
| BISPECIFIC ANTIBODY | ? unclear | Mechanistic | DGIdb | |
| CADONILIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| APLITHIANINE A | ↓ inhibits | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2A | ? unclear | Mechanistic | DGIdb | |
| INOSINE 5'-MONOPHOSPHATE DEHYDROGENASE INHIBITOR FF-10501-01 | ? unclear | Mechanistic | DGIdb | |
| ABATACEPT | ? unclear | Mechanistic | DGIdb | |
| WORTMANNIN | ? unclear | Mechanistic | DGIdb | |
| ERFONRILIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| THALIDOMIDE | ? unclear | Mechanistic | DGIdb | |
| FF-10501-01 | ? unclear | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| TETRADECANOYLPHORBOL ACETATE | ? unclear | Mechanistic | DGIdb | |
| DEHYDRATED ALCOHOL | ? unclear | Mechanistic | DGIdb | |
| PREDNISONE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL5291170 | ↓ inhibits | Mechanistic | 31000.0 nM (Kd) | ChEMBL |
DIO1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| PROPYLTHIOURACIL | ↓ inhibits | Mechanistic | DGIdb |
DIO2
Pipeline results not yet available for this target. Run the pipeline to populate.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| GENISTEIN | ? unclear | Mechanistic | DGIdb | |
| VITAMIN A | ? unclear | Mechanistic | DGIdb | |
| RECOMBINANT TRANSFORMING GROWTH FACTOR-BETA 1 | ? unclear | Mechanistic | DGIdb | |
| DEXAMETHASONE | ? unclear | Mechanistic | DGIdb | |
| ACEBUTOLOL | ? unclear | Mechanistic | DGIdb | |
| AZACITIDINE | ? unclear | Mechanistic | DGIdb | |
| VACCINE | ? unclear | Mechanistic | DGIdb | |
| AMINOGLYCOSIDE ANTIBIOTIC | ? unclear | Mechanistic | DGIdb | |
| FLUORODEOXYGLUCOSE F18 | ? unclear | Mechanistic | DGIdb | |
| CALCITRIOL | ? unclear | Mechanistic | DGIdb | |
| PREDNISONE | ? unclear | Mechanistic | DGIdb | |
| HEXAMETHYLENEBISACETAMIDE | ? unclear | Mechanistic | DGIdb | |
| PREDNISOLONE | ? unclear | Mechanistic | DGIdb | |
| ALDESLEUKIN | ? unclear | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2A | ? unclear | Mechanistic | DGIdb | |
| OCTREOTIDE ACETATE | ? unclear | Mechanistic | DGIdb | |
| DEHYDRATED ALCOHOL | ? unclear | Mechanistic | DGIdb | |
| ISOTRETINOIN | ? unclear | Mechanistic | DGIdb | |
| RETINOIC ACID AGENT | ? unclear | Mechanistic | DGIdb | |
| GAMMA-INTERFERON | ? unclear | Mechanistic | DGIdb | |
| PHENYTOIN SODIUM | ? unclear | Mechanistic | DGIdb | |
| AMIODARONE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| HEXAMETHYLENE BISACETAMIDE | ? unclear | Mechanistic | DGIdb | |
| POLYETHYLENE GLYCOL 4000 | ? unclear | Mechanistic | DGIdb | |
| ROSIGLITAZONE | ? unclear | Mechanistic | DGIdb | |
| TECHNETIUM TC 99M SESTAMIBI | ? unclear | Mechanistic | DGIdb | |
| BISPECIFIC ANTIBODY | ? unclear | Mechanistic | DGIdb | |
| AMINOGLUTETHIMIDE | ? unclear | Mechanistic | DGIdb | |
| ANTIDEPRESSANT AGENT | ? unclear | Mechanistic | DGIdb | |
| ADENOVIRUS VECTOR | ? unclear | Mechanistic | DGIdb | |
| TRETINOIN | ? unclear | Mechanistic | DGIdb |
THRA
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| ASPIRIN | ? unclear | Mechanistic | DGIdb | |
| LIOTHYRONINE | ↑ activates | Mechanistic | 0.1 nM (Kd) | DGIdb |
| LEVOTHYROXINE | ↑ activates | Mechanistic | DGIdb | |
| LIOTHYRONINE SODIUM | ↑ activates | Mechanistic | DGIdb | |
| TIRATRICOL | ? unclear | Mechanistic | 0.14 nM (IC50) | DGIdb |
| DEXTROTHYROXINE | ↑ activates | Mechanistic | DGIdb | |
| DEXTROTHYROXINE SODIUM | ↑ activates | Mechanistic | DGIdb | |
| LEVOTHYROXINE SODIUM | ? unclear | Mechanistic | Open Targets | |
| CHEMBL111953 | ↓ inhibits | Mechanistic | 490.0 nM (Kd) | ChEMBL |
| CHEMBL109430 | ↓ inhibits | Mechanistic | 5.2 nM (Kd) | ChEMBL |
| CHEMBL109279 | ↓ inhibits | Mechanistic | 93.0 nM (Kd) | ChEMBL |
| CHEMBL110158 | ↓ inhibits | Mechanistic | 330.0 nM (Kd) | ChEMBL |
| SOBETIROME | ↓ inhibits | Mechanistic | 1.8 nM (Kd) | ChEMBL |
| CHEMBL112087 | ↓ inhibits | Mechanistic | 200.0 nM (Kd) | ChEMBL |
| CHEMBL83953 | ↓ inhibits | Mechanistic | 39000.0 nM (IC50) | ChEMBL |
| CHEMBL86271 | ↓ inhibits | Mechanistic | 1800.0 nM (IC50) | ChEMBL |
| CHEMBL82131 | ↓ inhibits | Mechanistic | 18100.0 nM (IC50) | ChEMBL |
| CHEMBL85322 | ↓ inhibits | Mechanistic | 69000.0 nM (IC50) | ChEMBL |
| CHEMBL83829 | ↓ inhibits | Mechanistic | 930.0 nM (IC50) | ChEMBL |
| CHEMBL97187 | ↓ inhibits | Mechanistic | 1400.0 nM (Kd) | ChEMBL |
| CHEMBL318132 | ↓ inhibits | Mechanistic | 112.0 nM (Kd) | ChEMBL |
| CHEMBL97613 | ↓ inhibits | Mechanistic | 430.0 nM (Kd) | ChEMBL |
| CHEMBL98135 | ↓ inhibits | Mechanistic | 1400.0 nM (Kd) | ChEMBL |
| CHEMBL264527 | ↓ inhibits | Mechanistic | 240.0 nM (Kd) | ChEMBL |
| CHEMBL160883 | ↓ inhibits | Mechanistic | 820.0 nM (IC50) | ChEMBL |
| CHEMBL160703 | ↓ inhibits | Mechanistic | 1400.0 nM (IC50) | ChEMBL |
| AMIODARONE | ↓ inhibits | Mechanistic | 650.0 nM (IC50) | ChEMBL |
| CHEMBL157885 | ↓ inhibits | Mechanistic | 4500.0 nM (IC50) | ChEMBL |
| DETROTHYRONINE | ↓ inhibits | Mechanistic | 0.24 nM (IC50) | ChEMBL |
| CHEMBL39174 | ↓ inhibits | Mechanistic | 1.4 nM (IC50) | ChEMBL |
| THYROPROPIC ACID | ↓ inhibits | Mechanistic | 0.041 nM (IC50) | ChEMBL |
| CHEMBL40738 | ↓ inhibits | Mechanistic | 130.0 nM (IC50) | ChEMBL |
| CHEMBL289965 | ↓ inhibits | Mechanistic | 9.7 nM (IC50) | ChEMBL |
| CHEMBL41036 | ↓ inhibits | Mechanistic | 25.0 nM (IC50) | ChEMBL |
| CHEMBL289343 | ↓ inhibits | Mechanistic | 0.1 nM (IC50) | ChEMBL |
| CHEMBL418432 | ↓ inhibits | Mechanistic | 0.76 nM (IC50) | ChEMBL |
| CHEMBL41314 | ↓ inhibits | Mechanistic | 0.14 nM (IC50) | ChEMBL |
| CHEMBL125946 | ↑ activates | Mechanistic | 1500.0 nM (EC50) | ChEMBL |
| CHEMBL124205 | ↑ activates | Mechanistic | 12.0 nM (EC50) | ChEMBL |
| CHEMBL419016 | ↓ inhibits | Mechanistic | 2.4 nM (Kd) | ChEMBL |
Showing top 40 of 146 agents ranked by evidence tier.
THRB
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| METHYL PARATHIONE | ? unclear | Mechanistic | DGIdb | |
| DIENOCHLOR | ? unclear | Mechanistic | DGIdb | |
| AXITIROME | ? unclear | Mechanistic | DGIdb | |
| 3-METHYLCHOLANTHRENE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL577415 | ? unclear | Mechanistic | DGIdb | |
| DYCLONINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| LEVOTHYROXINE | ↑ activates | Mechanistic | DGIdb | |
| ORTHO-PHTHALALDEHYDE | ? unclear | Mechanistic | DGIdb | |
| QUINALIZARIN | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL297304 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1493528 | ? unclear | Mechanistic | DGIdb | |
| RESMETIROM | ↑ activates | Mechanistic | DGIdb | |
| CLOSANTEL | ? unclear | Mechanistic | DGIdb | |
| IDARUBICIN | ? unclear | Mechanistic | DGIdb | |
| FUMARPROTOCETRARIC ACID | ? unclear | Mechanistic | DGIdb | |
| DIPYRIDAMOLE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1341830 | ? unclear | Mechanistic | DGIdb | |
| CARUBICIN | ? unclear | Mechanistic | DGIdb | |
| ALBUTEROL SULFATE | ? unclear | Mechanistic | DGIdb | |
| PRIMAQUINE | ? unclear | Mechanistic | DGIdb | |
| DEXTROTHYROXINE SODIUM | ↑ activates | Mechanistic | DGIdb | |
| SOBETIROME | ↑ activates | Mechanistic | 0.1 nM (Kd) | DGIdb |
| METHYLENE BLUE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| HEXACHLOROPHENE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1465049 | ? unclear | Mechanistic | DGIdb | |
| COMPOUND 16G [PMID: 35507418] | ↑ activates | Mechanistic | DGIdb | |
| CHLOROTHALONIL | ? unclear | Mechanistic | DGIdb | |
| SLAZINIC ACID | ? unclear | Mechanistic | DGIdb | |
| TRIAMTERENE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL601952 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL578741 | ? unclear | Mechanistic | DGIdb | |
| CIRAZOLINE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL581044 | ? unclear | Mechanistic | DGIdb | |
| DAUNORUBICIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| RT3 | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL592124 | ? unclear | Mechanistic | DGIdb | |
| VK-2809 | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL602969 | ? unclear | Mechanistic | DGIdb | |
| EPROTIROME | ↑ activates | Mechanistic | DGIdb | |
| TOLONIUM CHLORIDE | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 253 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CARBIMAZOLE | ↓ inhibits | Mechanistic | DGIdb | |
| PROPYLTHIOURACIL | ↓ inhibits | Mechanistic | 3380.0 nM (IC50) | DGIdb |
| TRETINOIN | ? unclear | Mechanistic | DGIdb | |
| METHIMAZOLE | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL4278946 | ↓ inhibits | Mechanistic | 3900.0 nM (IC50) | ChEMBL |
| CHEMBL4282403 | ↓ inhibits | Mechanistic | 6000.0 nM (IC50) | ChEMBL |
| CHEMBL4482878 | ↓ inhibits | Mechanistic | 4000.0 nM (IC50) | ChEMBL |
| CHEMBL333928 | ↓ inhibits | Mechanistic | 42000.0 nM (IC50) | ChEMBL |
| CHEMBL4637728 | ↓ inhibits | Mechanistic | 30000.0 nM (IC50) | ChEMBL |
| CHEMBL4645343 | ↓ inhibits | Mechanistic | 5300.0 nM (IC50) | ChEMBL |
| CHEMBL4633000 | ↓ inhibits | Mechanistic | 5900.0 nM (IC50) | ChEMBL |
| CHEMBL4753981 | ↓ inhibits | Mechanistic | 2200.0 nM (IC50) | ChEMBL |
| CHEMBL4792720 | ↓ inhibits | Mechanistic | 6300.0 nM (IC50) | ChEMBL |
| CHEMBL4751166 | ↓ inhibits | Mechanistic | 59000.0 nM (IC50) | ChEMBL |
| CHEMBL4755252 | ↓ inhibits | Mechanistic | 12300.0 nM (IC50) | ChEMBL |
| CHEMBL4869433 | ↓ inhibits | Mechanistic | 700.0 nM (IC50) | ChEMBL |
| CHEMBL4859908 | ↓ inhibits | Mechanistic | 640.0 nM (IC50) | ChEMBL |
| CHEMBL4855030 | ↓ inhibits | Mechanistic | 2000.0 nM (IC50) | ChEMBL |
| CHEMBL4855931 | ↓ inhibits | Mechanistic | 710.0 nM (IC50) | ChEMBL |
| CHEMBL4846080 | ↓ inhibits | Mechanistic | 2300.0 nM (IC50) | ChEMBL |
| CHEMBL4853722 | ↓ inhibits | Mechanistic | 1100.0 nM (IC50) | ChEMBL |
| CHEMBL4863015 | ↓ inhibits | Mechanistic | 1100.0 nM (IC50) | ChEMBL |
| CHEMBL4871587 | ↓ inhibits | Mechanistic | 1800.0 nM (IC50) | ChEMBL |
| CHEMBL4855956 | ↓ inhibits | Mechanistic | 6700.0 nM (IC50) | ChEMBL |
| CHEMBL4878518 | ↓ inhibits | Mechanistic | 1900.0 nM (IC50) | ChEMBL |
| CHEMBL4862053 | ↓ inhibits | Mechanistic | 1100.0 nM (IC50) | ChEMBL |
| CHEMBL4860429 | ↓ inhibits | Mechanistic | 1700.0 nM (IC50) | ChEMBL |
| CHEMBL4877407 | ↓ inhibits | Mechanistic | 14000.0 nM (IC50) | ChEMBL |
| CHEMBL4859470 | ↓ inhibits | Mechanistic | 21000.0 nM (IC50) | ChEMBL |
| PF-06282999 | ↓ inhibits | Mechanistic | 990.0 nM (IC50) | ChEMBL |
| CHEMBL5200638 | ↓ inhibits | Mechanistic | 590.0 nM (IC50) | ChEMBL |
| CHEMBL5181827 | ↓ inhibits | Mechanistic | 4200.0 nM (IC50) | ChEMBL |
| CHEMBL5182747 | ↓ inhibits | Mechanistic | 8100.0 nM (IC50) | ChEMBL |
| CHEMBL5185576 | ↓ inhibits | Mechanistic | 1500.0 nM (IC50) | ChEMBL |
| CHEMBL5172456 | ↓ inhibits | Mechanistic | 1300.0 nM (IC50) | ChEMBL |
| CHEMBL5197968 | ↓ inhibits | Mechanistic | 1390.0 nM (IC50) | ChEMBL |
| CHEMBL5197383 | ↓ inhibits | Mechanistic | 3400.0 nM (IC50) | ChEMBL |
| CHEMBL5175091 | ↓ inhibits | Mechanistic | 1400.0 nM (IC50) | ChEMBL |
| CHEMBL5207346 | ↓ inhibits | Mechanistic | 4200.0 nM (IC50) | ChEMBL |
| CHEMBL5186129 | ↓ inhibits | Mechanistic | 1900.0 nM (IC50) | ChEMBL |
Showing top 40 of 55 agents ranked by evidence tier.
TSHR
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| PENTACHLOROPHENOL | ? unclear | Mechanistic | DGIdb | |
| THYROTROPIN ALFA | ↑ activates | Mechanistic | DGIdb | |
| CILOSTAZOL | ? unclear | Mechanistic | DGIdb | |
| ALPHA-NAPHTHOFLAVONE | ? unclear | Mechanistic | DGIdb | |
| GRAMINE | ? unclear | Mechanistic | DGIdb | |
| TESTOSTERONE PROPIONATE | ? unclear | Mechanistic | DGIdb | |
| SB 222200 | ? unclear | Mechanistic | DGIdb | |
| URAPIDIL | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL312032 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL578276 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL606166 | ? unclear | Mechanistic | DGIdb | |
| AM-630 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL607309 | ? unclear | Mechanistic | DGIdb | |
| LEVALBUTEROL | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL140220 | ? unclear | Mechanistic | DGIdb | |
| ICI-199441 | ? unclear | Mechanistic | DGIdb | |
| LASALOCID A SODIUM | ? unclear | Mechanistic | DGIdb | |
| CLOSANTEL | ? unclear | Mechanistic | DGIdb | |
| DIPYRIDAMOLE | ? unclear | Mechanistic | DGIdb | |
| ANTISERUM | ? unclear | Mechanistic | DGIdb | |
| ISOPROTERENOL | ? unclear | Mechanistic | DGIdb | |
| SEROTONIN | ? unclear | Mechanistic | DGIdb | |
| NMDA | ? unclear | Mechanistic | DGIdb | |
| BERGAMOTTIN | ? unclear | Mechanistic | DGIdb | |
| 3,6-DIMETHOXYFLAVONE | ? unclear | Mechanistic | DGIdb | |
| L-733,060 | ? unclear | Mechanistic | DGIdb | |
| TYRPHOSTIN AG 879 | ? unclear | Mechanistic | DGIdb | |
| CARBONYL CYANIDE M-CHLOROPHENYLHYDRAZONE | ? unclear | Mechanistic | DGIdb | |
| CP-339818 | ? unclear | Mechanistic | DGIdb | |
| DICHLOROPHEN | ? unclear | Mechanistic | DGIdb | |
| CLORGILINE | ? unclear | Mechanistic | DGIdb | |
| DEXPROPRANOLOL | ? unclear | Mechanistic | DGIdb | |
| TYRPHOSTIN A9 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL429095 | ? unclear | Mechanistic | DGIdb | |
| CLIOXANIDE | ? unclear | Mechanistic | DGIdb | |
| PIPERONYL BUTOXIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1456848 | ? unclear | Mechanistic | DGIdb | |
| KARANJIN | ? unclear | Mechanistic | DGIdb | |
| THYROTROPIN | ↑ activates | Mechanistic | DGIdb | |
| KINETIN | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 294 agents ranked by evidence tier.
Clinical Trials
Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Hypothyroidism: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.
Primary hypothyroidism is a common condition, affecting nearly 10% of the general population. Its treatment is levothyroxine, a synthetic thyroid hormone with a half-life of nearly eight days. Optimal absorption of levothyroxine occurs when it is taken on an empty stomach. It is generally recommende...
This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism and are currently stabilized (i.e., in-range thyroid-stimulating hormone \[TSH\]) on synthetic T4 treatment. This study will also therefore evaluate the...
This randomized controlled trial compared high-dose and moderate-dose levothyroxine as initial therapy for neonates with primary congenital hypothyroidism. One hundred one infants were randomized to receive either approximately 12.85 or 7.65 µg/kg/day. Thyroid function and dose adjustments were asse...
The North Star study is a multi-center, Phase 3, open-label, single-arm clinical study to evaluate the Efficacy and Safety of North Star therapy.
Hypothyroidism is a common condition, more frequent in females, associated with excess of cardiovascular risk and poor quality of life not completely abrogated by treatment with levothyroxine. There is an unmet need to define a safe, effective, and feasible regimen to be applied in large trials aime...
Our overall goal is to determine the clinical consequences of allowing greater flexibility in LT4 dosing in older individuals who take LT4.
The goal of this study is to find out whether hypothyroidism caused by immune checkpoint inhibitors (ICIs) can recover after stopping the ICIs. The study also aims to identify factors that can help predict which patients will be able to stop taking thyroid hormone replacement. The main questions the...
The North Star study is a multi-center, Phase 2, double-blind, randomized, parallel group clinical study to evaluate the safe and effective dose conversion from Levothyroxine to North Star therapy.
The goal of this clinical trial is to find out whether levothyroxine reduces complications and improves the prognosis of patients with subclinical hypothyroidism (SCH) undergoing coronary artery bypass grafting (CABG). The main questions this study aims to answer are: • Does levothyroxine reduce maj...
This study will be conducted to compare between the effect of nonlinear and linear periodized training on quality of life in females with hypothyroidism.
This is a non-randomized, open-label, single arm, self-controlled study of XP-8121 (levothyroxine sodium) to determine a target dose conversion factor from stably dosed oral levothyroxine to XP-8121 (levothyroxine sodium) in patients with hypothyroidism and to assess the safety and tolerability of X...
The goal of this clinical trial is to study the improvement of lipid levels in hypothyroid individuals after staring treatment. The main question it aims to answer is: • whether adding Vitamin D to standard therapy has any additional benefits Participants will be given Vitamin D in replacement doses...
Hypothyroidism is common, affecting 5% of the general population, for which levothyroxine (LT4) monotherapy is the standard treatment. Despite normalized serum thyroid hormone levels, 10-15% of LT4 treated patients have various persistent complaints, the most important of which is tiredness. This co...
STUDY OBJECTIVES 1. To assess the safety of Darqeen capsule for the management of Hypothyroidism 2. Evaluate the efficacy of Darqeen capsule for the management of Hypothyroidism 3. To provide an alternative cost-effective treatment for the management of females suffering from hypothyroidism. NULL HY...
ST-1891-201 is a multicenter, randomized, double-blind, partial crossover, Phase 2 study evaluating the safety and efficacy of hormone replacement therapy with ST-1891 compared to levothyroxine in patients with primary hypothyroidism.
Agents Found By Disease-Level Search
Searched directly from “Hypothyroidism” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 8-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
33 agents shown (approved or with trial evidence) — 28 not found by the gene-target search above.
Levothyroxine
levothyroxine sodium
L-carnitineNOT in gene-target list
Armour® ThyroidNOT in gene-target list
ST-1891NOT in gene-target list
MNP groupNOT in gene-target list
Quantitative POC TSH KitNOT in gene-target list
Qualitative POC TSH KitNOT in gene-target list
Third generation TSH KitNOT in gene-target list
Liothyronine, Sodium
LT3 (liothyronine)NOT in gene-target list
management of therapy complicationsNOT in gene-target list
Eltroxin administrationNOT in gene-target list
ThyroxineNOT in gene-target list
Serum thyroid function testsNOT in gene-target list
TRH (Thyrotropin Releasing Hormone)NOT in gene-target list
Assesment of thyroïd functionNOT in gene-target list
Liothyronine
D-THIO (Deprescribing Thyroid Hormone In Older Adults)NOT in gene-target list
L-thyroxineNOT in gene-target list
Clinical Pharmacist Intervention GroupNOT in gene-target list
Levothyroxine/Liothyronine once dailyNOT in gene-target list
Levothyroxine/Liothyronine twice dailyNOT in gene-target list
Levothyroxine sodium new formulationNOT in gene-target list
Brand Name Levothyroxine (Synthroid)NOT in gene-target list
Generic formulation of LevothyroxineNOT in gene-target list
iodinated contrast agentsNOT in gene-target list
THYROTROPIN
OMEGA-3-ACID ETHYL ESTERSNOT in gene-target list
CHOLESTYRAMINENOT in gene-target list
FENOFIBRATENOT in gene-target list
MECASERMINNOT in gene-target list
THYROGLOBULINNOT in gene-target list
Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.